Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Observational data published over the past decade have suggested that concomitant receipt of piperacillin-tazobactam with vancomycin significantly increases the risk for vancomycin-associated acute kidney injury. Importantly, however, there is significant controversy surrounding this association, and debate continues about the veracity of the risk. Given this ongoing debate, the recently published "Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial" is of tremendous interest to the infectious diseases community. In ACORN, the authors conclude that there was no association between receipt of cefepime or piperacillin-tazobactam and the primary outcome of acute kidney injury or death by day 14, despite the fact that >75% of the population received concomitant vancomycin. In this perspective, we provide a brief history on the controversy, provide a critical analysis of the ACORN findings, and ultimately discuss how these data help inform the ongoing debate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 11(2024), 1 vom: 08. Jan., Seite ofad645 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pogue, Jason M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACORN |
|---|
| Anmerkungen: |
Date Revised 21.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad645 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36730340X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36730340X | ||
| 003 | DE-627 | ||
| 005 | 20240121231953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad645 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1266.xml |
| 035 | |a (DE-627)NLM36730340X | ||
| 035 | |a (NLM)38239847 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pogue, Jason M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Observational data published over the past decade have suggested that concomitant receipt of piperacillin-tazobactam with vancomycin significantly increases the risk for vancomycin-associated acute kidney injury. Importantly, however, there is significant controversy surrounding this association, and debate continues about the veracity of the risk. Given this ongoing debate, the recently published "Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial" is of tremendous interest to the infectious diseases community. In ACORN, the authors conclude that there was no association between receipt of cefepime or piperacillin-tazobactam and the primary outcome of acute kidney injury or death by day 14, despite the fact that >75% of the population received concomitant vancomycin. In this perspective, we provide a brief history on the controversy, provide a critical analysis of the ACORN findings, and ultimately discuss how these data help inform the ongoing debate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACORN | |
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a nephrotoxicity | |
| 650 | 4 | |a piperacillin-tazobactam | |
| 650 | 4 | |a vancomycin | |
| 700 | 1 | |a Aitken, Samuel L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 11(2024), 1 vom: 08. Jan., Seite ofad645 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:1 |g day:08 |g month:01 |g pages:ofad645 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad645 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 1 |b 08 |c 01 |h ofad645 | ||